Publications


At PamGene we have developed a robust and unique microarray technology for multiplex kinase activity profiling. On this page you will find a selection of scientific publications where PamGene’s technology has been applied.

Publications


At PamGene we have developed a robust and unique microarray technology for multiplex kinase activity profiling. On this page you will find a selection of scientific publications where PamGene’s technology has been applied.

Diagnostics

Peptide microarrays for detailed, high-throughput substrate identification, kinetic characterization, and inhibition studies on protein kinase.

A. Hilhorst R. et al.

Anal. Biochem. 387, 150–161 (2009).

Read more

Phosphoproteomic and Kinomic Signature of Clinically Aggressive Grade I (1.5) Meningiomas Reveals Rb1 signaling as a Novel Mediator and Biomarker.

Parada, C. A. et al.

Clin. Cancer Res. clincanres.0641.2018 (2020)

Read more

Systemic analysis of tyrosine kinase signaling reveals a common adaptive response program in a HER2-positive breast cancer.

Schwill, M. et al.

Sci. Signal. 12, (2019).

Read more

Identification of new possible targets for leukemia treatment by kinase activity profiling.

Ter Elst, A. et al.

Leuk. Lymphoma 52, 122–130 (2011).

Read more

Inactive immune pathways in triple negative breast cancers that showed resistance to neoadjuvant chemotherapy as inferred from kinase activity profiles.

Sawada, T. et al.

Oncotarget 9, 34229–34239 (2018).

Read more

Profiling activity of cellular kinases in migrating T-cells.

Chirumamilla, C. S. et al.

Methods Mol. Biol. 1930, 99–113 (2019).

Read more

Differential Kinase Activation in Peripheral Blood Mononuclear Cells from Non-Small-Cell Lung Cancer Patients Treated with Nivolumab.

Noé, G. et al.

Cancers (Basel). 11, 762 (2019).

Read more

Blood-based multiplex kinase activity profiling as a predictive marker for clinical response to checkpoint blockade in advanced melanoma.

Hurkmans, D. et al.

J. Clin. Oncol. 36, 9579 (2018).

Read more

Blood-Based Multiplex Kinase Activity Profiling as a Predictive Marker for Clinical Response to Checkpoint Blockade in Advanced NSCLC.

Hurkmans, D. et al. P2.04-06

J. Thorac. Oncol. 14, S709 (2019).

Read more

Biomarker discovery

The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy.

Havel JJ et al.

Nat. Rev. Cancer 19, 133–150 (2019).

Read more

Profiling of human lymphocytes reveals a specific network of protein kinases modulated by endurance training status.

Alack, K. et al.

Sci Rep. Jan 21;10(1):888 (2020).

Read more

Clinical and kinomic analysis identifies peripheral blood mononuclear cells as a potential pharmacodynamic biomarker in metastatic renal cell carcinoma patients treated with sunitinib.

Noé G, Bellesoeur A, Thomas-Schoemann A, Rangarajan S, Naji F, Puszkiel A, Huillard O, Saidu N, Golmard L, Alexandre J, Goldwasser F, Blanchet B, Vidal M.

Oncotarget. Aug 29. (2016)

Read more

Kinase Inhibitor Discovery

The ALK inhibitor AZD3463 effectively inhibits growth of sorafenib-resistant acute myeloid leukemia.

Moharram SA, Shah K, Khanum F, Rönnstrand L, Kazi JU. (2019)

Blood Cancer J. Jan 15;9(2):5.

Read more

Intratumoral spatial heterogeneity of BTK kinomic activity dictates distinct therapeutic response within a single glioblastoma tumor.

Ibrahim AN, Yamashita D, Anderson JC, Abdelrashid M, Alwakeal A, Estevez-Ordonez D, Komarova S, Markert JM, Goidts V, Willey CD, Nakano I. 

J Neurosurg. Oct 18:1-12.(2019)

Read more

Kinase Inhibitor Optimization

Differential Inhibition of Ex-Vivo Tumor Kinase Activity by Vemurafenib in BRAF(V600E) and BRAF Wild-Type Metastatic Malignant Melanoma.

Tahiri, A. et al.

PLoS One 8, (2013).

Read more

Multiparametric Assessment of the Effects of Tyrosine Kinase Inhibitors (TKIs) on the (Electro)physiology of Human Induced Pluripotent Stem Cell (hiPSC)-Derived Cardiomyocytes.

de Korte T, Nacken P, Pijnenburg D, Ruijtenbeek R, Stevenhagen F, Wilbers R, den Hartogh S, Groten J, Braam S and Vlaming M

Journal of Pharmacological and Toxicological Methods. 88. 236-237. 10.1016. (2017) 

Read more

Molecular mechanism underlying the pharmacological interactions of the protein kinase C-β inhibitor enzastaurin and erlotinib in non-small cell lung cancer cells.

Steen NV, Potze L, Giovannetti E, Cavazzoni A, Ruijtenbeek R, Rolfo C, Pauwels P, Peters GJ. 

Am J Cancer Res. Apr 1;7(4):816-830. eCollection 2017.

Read more

Target discovery

Targeting cyclin-dependent kinases for the treatment of pulmonary arterial hypertension.

Weiss A, Neubauer MC, Yerabolu D, Kojonazarov B, Schlueter BC, Neubert L, Jonigk D, Baal N, Ruppert C, Dorfmuller P, Pullamsetti SS, Weissmann N, Ghofrani HA, Grimminger F, Seeger W, Schermuly RT.

Nat Commun. May 17;10(1):2204.(2019) 

Read more

ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer.

Cato L, de Tribolet-Hardy J, Lee I, Rottenberg JT, Coleman I, Melchers D, Houtman R, Xiao T, Li W, Uo T, Sun S, Kuznik NC, Göppert B, Ozgun F, van Royen ME, Houtsmuller AB, Vadhi R, Rao PK, Li L, Balk SP, Den RB, Trock BJ, Karnes RJ, Jenkins RB, Klein EA, Davicioni E, Gruhl FJ, Long HW, Liu XS, Cato ACB, Lack NA, Nelson PS, Plymate SR, Groner AC, Brown M.

Cancer Cell. Mar 18;35(3):401-413. (2019)

Read more

Rational development of synergistic combinations of chemotherapy and molecular targeted agents for colorectal cancer treatment.

Tosi D, Pérez-Gracia E, Atis S, Vié N, Combès E, Gabanou M, Larbouret C, Jarlier M, Mollevi C, Torro A, Del Rio M, Martineau P, Gongora C.

BMC Cancer. Aug 13;18(1):812. (2018) 

Read more

Target interaction

Metformin induces lipogenic differentiation in myofibroblasts to reverse lung fibrosis.

Kheirollahi V, Wasnick RM, Biasin V, Vazquez-Armendariz AI, Chu X, Moiseenko A, Weiss A, Wilhelm J, Zhang JS, Kwapiszewska G, Herold S, Schermuly RT, Mari B, Li X, Seeger W, Günther A, Bellusci S, El Agha E.

Nat Commun. Jul 5;10(1):2987. (2019)

Read more

Mechanically activated Piezo1 channels of cardiac fibroblasts stimulate p38 mitogen-activated protein kinase activity and interleukin-6 secretion.

Blythe NM, Muraki K, Ludlow MJ, Stylianidis V, Gilbert HTJ, Evans EL, Cuthbertson K, Foster R, Swift J, Li J, Drinkhill MJ, van Nieuwenhoven FA, Porter KE, Beech DJ, Turner NA.

J Biol Chem. Oct 4. pii: jbc.RA119.009167. doi: 10.1074/jbc.RA119.009167. EPub. (2019) 

Read more

Decrease in phospho-PRAS40 plays a role in the synergy between erlotinib and crizotinib in an EGFR and cMET wild-type squamous non-small cell lung cancer cell line.

Van Der Steen N, Leonetti A, Keller K, Dekker H, Funel N, Lardon F, Ruijtenbeek R, Tiseo M, Rolfo C, Pauwels P, Peters GJ, Giovannetti E.

Biochem Pharmacol. 2019 Aug;166:128-138. (2019) 

Read more

Biochemical characterization

Analysis of Jak2 catalytic function by peptide microarrays: the role of the JH2 domain and V617F mutation.

Sanz A, Ungureanu D, Pekkala T, Ruijtenbeek R, Touw IP, Hilhorst R, Silvennoinen O.

PLoS One. (2011) Apr 18;6(4):e18522.

Read more

Peptide microarrays for detailed, high-throughput substrate identification, kinetic characterization, and inhibition studies on protein kinase.

A. Hilhorst R, Houkes L, van den Berg A, Ruijtenbeek R.

Anal Biochem. (2009) Apr 15;387 (2): 150-61.

Read more

Compound-based patient stratification

Lithium effects on serine-threonine kinases activity: high throughput Kinomic Profiling of lymphoblastoid cell lines from excellent-responders and non-responders bipolar patients.

Moreira J, Noe G, Rangarajan S, Courtin C, Etain B, Geoffroy PA, Laplanche JL, Vidal M, Bellivier F and Marie-Claire C

The World Journal of Biological Psychiatry (2018) 

Read more

Diseases Model characterization

Large-scale reduction of tyrosine kinase activities in human monocytes stimulated in vitro with N. meningitidis.

Gopinathan, U. et al.

PLoS One 13, 1–23 (2018).

Read more

Neuronal impact of patient-specific aberrant NRXN1α splicing.

Flaherty E, Zhu S, Barretto N, Cheng E, Deans PJM, Fernando MB, Schrode N, Francoeur N, Antoine A, Alganem K, Halpern M, Deikus G, Shah H, Fitzgerald M, Ladran I, Gochman P, Rapoport J, Tsankova NM, McCullumsmith R, Hoffman GE, Sebra R, Fang G, Brennand KJ.

 Nat Genet. Dec;51(12):1679-1690. (2019).

Read more

Intratumoral spatial heterogeneity of BTK kinomic activity dictates distinct therapeutic response within a single glioblastoma tumor.

Ibrahim AN, Yamashita D, Anderson JC, Abdelrashid M, Alwakeal A, Estevez-Ordonez D, Komarova S, Markert JM, Goidts V, Willey CD, Nakano I.

J Neurosurg. Oct 18:1-12. (2019) 

Read more

Systemic analysis of tyrosine kinase signaling reveals a common adaptive response program in a HER2-positive breast cancer.

Schwill M, Tamaskovic R, Gajadhar AS, Kast F, White FM, Plückthun A.

Sci Signal. Jan 22;12(565) (2019) 

Read more

Pathway elucidation

STAT5-regulated microRNA-193b controls haematopoietic stem and progenitor cell expansion by modulating cytokine receptor signalling.

Haetscher N, Feuermann Y, Wingert S, Rehage M, Thalheimer FB, Weiser C, Bohnenberger H, Jung K, Schroeder T, Serve H, Oellerich T, Hennighausen L, Rieger MA.

Nat Commun. Nov 25;6:8928. (2015) 

Read more

Inactive immune pathways in triple negative breast cancers that showed resistance to neoadjuvant chemotherapy as inferred from kinase activity profiles.

Sawada T, Hilhorst R, Rangarajan S, Yoshida M, Tanabe Y, Tamura K, Kinoshita T, Shimoyama T, van Beuningen R, Ruijtenbeek R, Tsuda H, Koizumi F.

Oncotarget. Sep 28;9(76):34229-34239. (2018) 

Read more

Reversion of resistance to oxaliplatin by inhibition of p38 MAPK in colorectal cancer cell lines: involvement of the calpain / Nox1 pathway.

Chocry M, Leloup L, Kovacic H.

Oncotarget. 2017 Oct 10;8(61):103710-103730.

Read more

Novel EPHB4 Receptor Tyrosine Kinase Mutations and Kinomic Pathway Analysis in Lung Cancer.

Ferguson BD, Tan YH, Kanteti RS, Liu R, Gayed MJ, Vokes EE, Ferguson MK, Iafrate AJ, Gill PS, Salgia R.

 Sci Rep. 5:10641. doi: 10.1038/srep10641. (2015)

Read more